mn-001

Generic: tipelukast·Code: MN-001

mn-001: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.

Development Pipeline (1)

Clinical Trials (1)

A Randomized, Placebo-Controlled, Double-Blind Six Month Study Followed by an Open-Label Extension Phase to Evaluate the Efficacy, Safety and Tolerability of MN-001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

NCT02503657·Phase 2·MNOV
Completed

Frequently asked questions

Who is developing mn-001?

mn-001 is being developed by MEDICINOVA INC.

How many clinical trials involve mn-001?

BioSniper tracks 1 clinical trial involving mn-001.

Get deeper analysis on mn-001

Full trial data, mechanism of action, competitive landscape, and AI-powered insights.

Start Free Analysis
    mn-001 — Drug Pipeline, Trials & FDA Status | BioSniper